Teva Pharmaceutical Industries Limited (TEVA) - Long-Term Debt to Capital Coefficient

Teva Pharmaceuticals - graphic logo of issuer TEVA

The share price history of Teva Pharmaceutical Industries (TEVA) confirms the resilience of a business built on the mass production of affordable generics and the development of unique CNS therapies. Teva Pharmaceutical Industries (TEVA) is overcoming a prolonged downturn, transitioning to a stage of profitable biosimilar development. Massive production scales provide a hedge against severe pricing pressure, and the current metric stands at 1.57, underscoring the holding's significance in global healthcare.

Teva Pharmaceutical Industries (TEVA): Long-Term Debt to Equity from 07/04/2022 to 11/01/2026

Comprehensive metric breakdowns and analytics for Teva Pharmaceutical Industries Limited (TEVA)

- stock price and consensus target price:
Quote Chart Teva|TEVA - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Teva Pharmaceuticals|TEVA - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Teva|TEVA - Company Book Value|Market Value to Book Value tevapharm.com|TEVA - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Teva Pharmaceutical Industries|TEVA - Long-Term Debt to Capital|Short-Term Debt to Capital Teva Pharma|TEVA - Company Total Debt|Debt to Net Assets Ratio Teva Pharmaceuticals|TEVA - Company Long-Term Debts|Company Short-Term Loans and Borrowings Teva|Immediate Liquidity tevapharm.com
- net income and valuation ratios data:
TEVA - Company Net Income
General company analysis:Teva Pharmaceutical Industries - TEVA
Signature product of Teva Pharmaceutical Industries Limited

When selecting defensive assets, a low debt-to-equity ratio becomes the priority. Teva Pharmaceutical Industries (TEVA) investments in packaging line automation and AI-driven control reduce costs, which is reflected in the long-term debt-to-equity trend. This metric measures the proportion of loans with a maturity of more than one year, allowing for an assessment of financial leverage stability and the risk of capital freeze.

Key competitors

Lilly - Long-Term Liabilities to Equity|Long-Term Debt to Capital ABBV|AZN (AstraZeneca Corp.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital NVS (Novartis AG)|Long-Term Debt to Capital merck.com MRK|NVO - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient AMGN (Amgen Corp)|Pfizer Corporation (PFE) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Sanofi Group|BMY (Bristol-Myers Squibb) - Long-Term Debt to Capital|Long-Term Debt to Capital GSK Corp|Long-Term Debt to Equity Ratio TAK (Takeda)|RDY (Dr. Reddy's Laboratories Limited) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital VTRS (Viatris Corp)|Long-Term Debt to Capital Coefficient ROIV|ZLAB - Long-Term Debt to Equity|Long-Term Liabilities to Capital bauschhealth.com|Cosmos Health (COSM) - Long-Term Debt to Equity